Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Conditions: AL Amyloidosis; Smoldering Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance Interventions: Other: no intervention Sponsors: IRCCS Policlinico S. Matteo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: CLN-619 Sponsors: Cullinan Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection Sponsors: Changzhou No.2 People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Conditions: Relapsed or Refractory Multiple Myeloma Interventions: Drug: SIM0500 Sponsors: Jiangsu Simcere Pharmaceutical Co., Ltd.; Shanghai Xianxiang Medical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Biological: Linvoseltamab Sponsors: Dickran Kazandjian, MD; Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Conditions: Relapsed/Refractory Multiple Myeloma Interventions: Drug: Equecabtagene Autoleucel Sponsors: Peking University People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
Conditions: Multiple Myeloma Sponsors: The First Affiliated Hospital of Soochow University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Conditions: Smoldering Multiple Myeloma Sponsors: Tufts Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Real-World Study of Bispecific Antibodies in Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Other: Treated by bispecific antibodies, teclistamab or elranatamab in usual care; Other: Not treated by bispecific antibodies in usual care Sponsors: Assistance Publique - H ôpitaux de Paris Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Study of SYS6020 in BCMA-positive Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Biological: BCMA Targeted CAR T-cells Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Crizotinib; Procedure: Radiologic Examination Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy
Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukaemia; Multiple Myeloma Interventions: Biological: Idecabtagene vicleucel; Biological: Lisocabtagene maraleucel Sponsors: Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Crizotinib; Procedure: Radiologic Examination Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Procedure: Radionuclide Imaging; Drug: Vismodegib Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Conditions: Plasma Cell Myeloma Refractory Interventions: Drug: Isatuximab SC-OBDS; Drug: Montelukast; Drug: Dexamethasone; Drug: Acetaminophen; Drug: Diphenhydramine; Drug: Methylprednisolone; Drug: Carfilzomib Sponsors: Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
